Recurrent implantation failure (RIF) — typically defined as failure to achieve an ongoing pregnancy after three or more ICI or IUI cycles with good-quality embryos or sperm — is one of the most frustrating clinical scenarios in fertility medicine. It suggests that factors beyond timing and sperm quality are preventing conception, and demands a systematic diagnostic approach rather than continued empirical cycling.
Defining and Diagnosing RIF in ICI Context
The definition of recurrent implantation failure in the ICI context differs from the IVF context where the term originated. For ICI patients, a working definition of three or more cycles with confirmed ovulation, adequate sperm parameters, appropriate timing, and a normal uterine cavity on prior evaluation — without even a chemical pregnancy — is a reasonable threshold at which a systematic diagnostic workup is indicated. Some practitioners set the threshold at three failed cycles for women under 37 and two for women over 37, reflecting the urgency of age-related decline.
The diagnostic framework for ICI-context RIF begins by confirming that the basic variables have been optimized: ovulation was confirmed (not assumed), timing was within the fertile window (LH surge detected and insemination within 24–36 hours), sperm quality was verified (post-thaw motility data obtained for donor sperm, or semen analysis obtained for partner sperm), and the uterine cavity has been evaluated (SIS or hysteroscopy performed). Failure to confirm any of these variables means that ‘recurrent failure’ may actually be ‘recurrent cycle errors’ — a different problem with a different solution. True RIF workup proceeds only after these baseline variables are confirmed.
Uterine Factors in RIF
After basic variable confirmation, uterine factor evaluation is the most productive first diagnostic category for RIF. Findings missed on standard ultrasound that are detected on detailed evaluation include: small submucosal fibroids or polyps (endometrial polyps are found in 20–30% of women with unexplained infertility and may impair implantation through mechanical and biochemical mechanisms), intrauterine adhesions (Asherman’s syndrome — may be present even without prior intrauterine surgery if there has been prior infection or instrumentation), uterine septum (the most common uterine congenital anomaly, associated with recurrent pregnancy loss and potentially implantation failure), and chronic endometritis (inflammation of the endometrial lining, often detected only on biopsy as plasma cells in the endometrial stroma).
Chronic endometritis deserves special emphasis because it is underdiagnosed and highly treatable. A 2019 study in Fertility and Sterility found chronic endometritis in 23% of women with unexplained recurrent implantation failure, compared to 2.8% of controls. It is diagnosed by endometrial biopsy showing plasma cells on CD138 immunostaining — a test not performed on standard endometrial biopsy. Treatment with a 14-day course of antibiotics (doxycycline 100 mg twice daily is first-line; broader-spectrum regimens for refractory cases) and confirmation of resolution on repeat biopsy has been associated with significant improvement in subsequent implantation rates. For ICI candidates with RIF who have never had chronic endometritis testing, adding this evaluation is high-yield.
Immunological and Thrombophilic Workup
Immunological and thrombophilic testing becomes relevant in RIF, particularly when there is a history of early pregnancy loss (chemical pregnancies or losses before 8–10 weeks) rather than complete failure to implant. Testing appropriate for this evaluation includes: antiphospholipid antibodies (lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2GPI IgG/IgM), thrombophilia screening (Factor V Leiden mutation, Prothrombin G20210A mutation, protein C and S, antithrombin III) in women with personal or family history of thrombosis, and thyroid function with thyroid antibodies (TPO, TG). Inherited thrombophilias are associated with first-trimester loss through placental microthrombi but have inconsistent association with pre-implantation failure.
NK cell testing and reproductive immunology panels beyond the above are not supported by consistent evidence for routine RIF workup and should be considered investigational. The RCOG’s guideline on recurrent miscarriage specifically states that peripheral blood NK cell testing is not recommended outside of research protocols. For ICI candidates considering reproductive immunology consultation, asking specifically which tests have RCT evidence supporting treatment decisions — versus those offered as exploratory investigations — helps distinguish evidence-based workup from the investigational approaches that are common but not yet standard of care.
When to Transition from ICI to More Intensive Treatment
The appropriate transition from ICI to IUI or IVF in the setting of confirmed RIF depends on which diagnostic category the workup reveals. If uterine pathology is found and corrected (fibroid removed, polyp resected, endometritis treated), returning to ICI after treatment is reasonable before assuming the condition is refractory. If the workup reveals no identifiable cause — true unexplained RIF — the decision to escalate to IUI (which eliminates the cervical transit step) or IVF (which allows embryo selection and uterine transfer under direct visualization) is appropriate at the discretion of the patient and her reproductive endocrinologist.
IVF with preimplantation genetic testing for aneuploidy (PGT-A) is the highest-information intervention available for unexplained RIF in women under 40 with adequate ovarian reserve. By testing embryos before transfer, PGT-A identifies euploid (chromosomally normal) embryos for transfer — directly addressing the aneuploidy hypothesis for unexplained implantation failure. Studies consistently show that PGT-A in unexplained RIF patients produces single-embryo transfer implantation rates of 50–70%, substantially higher than unscreened embryo transfers. The decision to proceed to IVF+PGT-A is a significant financial and procedural step, but for patients who have exhausted correctable causes through systematic workup, it provides a level of diagnostic and therapeutic certainty unavailable through continued ICI.
For a complete at-home insemination solution, the MakeAmom Babymaker Kit includes everything you need for a properly timed, sterile ICI cycle. For a complete at-home insemination solution, the His Fertility Boost includes everything you need for a properly timed, sterile ICI cycle.
Further reading across our network: IntracervicalInsemination.org · MakeAmom.com · IntracervicalInseminationKit.info
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making decisions about your fertility care.